Aging, angiotensin system and dopaminergic degeneration in the substantia nigra

Aging and Disease

Volumn 2, Issue 3, 2011, Pages 257-274

  Labandeira Garcia, Jose L ^a,b   Rodriguez Pallares, Jannette ^a,b   Villar Cheda, Begoña ^a,b   Rodríguez Perez, Ana I ^a,b   Garrido Gil, Pablo ^a,b   Guerra, Maria J ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Dopamine; Menopause; Neurodegeneration; Neuroinflammation; Oxidative stress; Parkinson; Renin angiotensin system

Indexed keywords

ANIMALIA; MUS; RATTUS;

EID: 84861695948     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (199)

1. Carlsson A, Falck B, Hillarp NA (1962). Cellular localization of brain monoamines. Acta Physiol Scand Suppl, 56: 1-28.
2. de Lau LM, Breteler MM (2006). Epidemiology of Parkinson's disease. Lancet Neurol, 5(6): 525-35.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55: 181-184.
4. Bergman H, Deuschl G (2002). Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord, 17 Suppl 3: 28-40.
5. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, Derkinderen P (2009). The second brain and Parkinson's disease. Eur J Neurosci, 30(5): 735-41.
6. Olanow CW (2007). The pathogenesis of cell death in Parkinson's disease. Mov Disord, 22 Suppl 17: S335-342.
7. Andersen JK (2004). Oxidative stress in neurodegeneration: cause or consequence. Nat Med, 10: S18-25.
8. Berg D, Youdim MB, Riederer P (2004). Redox imbalance. Cell Tissue Res, 318: 201-213.
9. Olanow CW (1990). Oxidation reactions in Parkinsońs disease. Neurology, 40 Suppl 3: 32-39.
10. Fahn S, Cohen G (1992). The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol, 32: 804-812.
11. Babior B (1999). NADPH oxidase: an update. Blood, 93: 1464-1476.
12. Babior BM (2004). NADPH oxidase. Curr Opin Immunol, 16: 42-47.
13. Cai H (2005). NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res, 96: 818-22.
14. Alberici LC, Oliveira HC, Paim BA, Mantello CC, Augusto AC, Zecchin KG, Gurgueira S A, Kowaltowski AJ, Vercesi A E (2009). Mitochondrial ATP-sensitive K(+) channels as redox signals to liver mitochondria in response to hypertriglyceridemia. Free Radic. Biol. Med, 47: 1432-1439.
15. Sheh YL, Hsu C, Chan SH, Chan JY (2007). NADPH oxidase- and mitochondrion-derived superoxide at rostral ventrolateral medulla in endotoxin-induced cardiovascular depression. Free Radic Biol Med, 42(10): 1610-23.
16. Zhang GX, Lu XM, Kimura S, Nishiyama A (2007). Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res, 76: 204-212.
17. Griendling KK, Sorescu D, Ushio-Fukai M (2000). NADPH oxidase. Role in cardiovascular biology and disease. Circulation Res, 86: 494-501.
18. Noh KM, Koh JY (2000). Induction and activation by Zinc of NADH oxidase in cultured cortical neurons and astrocytes. J Neurosci, 20: RC111 (1-5).
19. Münzel T, Keany JF (2001). Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation, 104: 1571-1577.
20. Mehta PK, Griendling KK (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol, 292(1): C82-97.
21. Touyz RM (2004). Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res, 37: 1263-1273.
22. Garrido AM, Griendling KK (2009). NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol, 302(2): 148-158.
23. Serrano F, Kolluri NS, Wientjes FB, Card JP, Klann E (2003). NADPH oxidase immunoreactivity in the mouse brain. Brain Res, 998: 193-98.
24. Phox distributions in rat brain. Brain Res, 1040(1-2): 178-86.
25. Gao HM, Hong JS, Zhang W, Liu B (2002). Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci, 22: 782-790.
26. Gao HM, Liu B, Zhang W, Hong JS (2003). Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J, 17: 1954-1956.
27. Wu D, Teisman P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsons disease. Proc. Natl. Acad. Sci. USA, 100: 6145-6150.
28. Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL (2007). Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem, 103: 145-156.
29. Reeves EP, Lu H, Jacobs HL, Messina CG, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal AW (2002). Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature, 416(6878): 291-7.
30. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS (2004). NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem, 279: 1415-1421.
31. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S (2001). The role of glial cells in Parkinson's disease. Curr Opin Neurol, 14: 483-489.
32. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E and Isacson O (2002). Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci, 15: 991-998.
33. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH (2003). Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci, 18: 2731-2742.
34. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP (1997). PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res, 50: 345-353.
35. Collier TJ, Lipton J, Daley BF, PalfiS, Chu Y, Sortwell C, Bakay RA, Sladek JR Jr, Kordower JH (2007). Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis, 26: 56-65.
36. Deng XH, Bertini G, Xu YZ, Yan Z, Bentivoglio M (2006). Cytokine-induced activation of glial cells in the mouse brain is enhanced at an advanced age. Neuroscience, 141: 645-61.
37. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM (2004). Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol, 471: 387-95.
38. Schallert T (1988). Aging-dependent emergence of sensorimotor dysfunction in rats recovered from dopamine depletion sustained early in life. Ann N Y Acad Sci, 515:108-20.
39. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988). Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol, 24: 574-576.
40. Fearnley JM, Lees AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114: 2283-2301.
41. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC (2000). Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain, 123: 366-373.
42. Villar-Cheda B, Sousa-Ribeiro D, Rodriguez-Pallares J, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL (2009). Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J Cereb Blood Flow Metab, 29: 230-39.
43. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G (2003). Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J, 17: 1183-5.
44. Ungvari Z, Csiszar A, Kaley G (2004). Vascular inflammation in aging. Herz, 29: 733-40.
45. Choi DY, Zhang J, Bing G (2010). Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. Neurobiol Aging, 31(9): 1649-53.
46. Tigerstedt R, Bergman P (1898). Niere und Kreislauf. Skand Arch Physiol, 8: 223-271.
47. Braun-Menendez E, Fasciolo JC, Leloir LF, Muñoz JM (1940). The substance causing renal hypertension. J Physiol, 98(3): 283-98.
48. Page IH, Helmer OM (1940). A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med, 71(1):29-42.
49. Smith HW. From fish to phylosopher. Boston: Little, Brown; 1953.
50. Lev-Ran A, Porta M (2005). Salt and hypertension: a phylogenetic perspective. Diabetes Metab Res Rev, 21(2):118-31.
51. Allen AM, Moeller I, Jenkins A, Zhuo J, Aldred GP, Chai SY, Mendelsohn FAO (1998). Angiotensin receptors in the nervous system. Brain Res Bull, 47: 17-8.
52. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu Y-Z (1996). Angiotensin receptors. J Hypertens, 14 (suppl. 5): S95-103.
53. Sasamura H, Hein L, Saruta T, Pratt RE (1997). Evidence for internalization of both type 1 angiotensin receptor subtypes (AT1a, AT1b) by a protein kinase C independent mechanism. Hypertens Res, 20(4): 295-300.
54. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev, 52(3): 415-72.
55. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T (1993). Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem, 268(33):24543-6.
56. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ (1993). Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun, 197(2):393-9.
57. Gard PR (2002). The role of angiotensin II in cognition and behaviour. Eur J Pharmacol, 438(1-2): 1-14.
58. Rosenstiel P, Gallinat S, Arlt A, Unger T, Sievers J, Lucius R (2002). Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease? CNS Drugs, 16(3):145-53.
59. Rodriguez-Pallares J, Quiroz CR, Parga JA, Guerra MJ, Labandeira-Garcia JL (2004). Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci, 20: 1489-1498.
60. Steckelings UM, Kaschina E, Unger T (2005). The AT2 receptor--a matter of love and hate. Peptides, 26(8):1401-9.
61. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Islam S, Welch WJ, Wilcox CF (2003). Effect of Ang II type 1 and 2 receptors on oxidative stress, renal NAD(P)H oxidase, and SOD expresion. Am J Physisiol Regu Integr Comp Physiol, 285: R117-124.
62. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE (2008). AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther, 120(3): 292-316.
63. Ganong WF (1994). Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med, 205: 213-19.
64. Re RN (2004).Tissue renin angiotensin systems. Med Clin North Am, 88: 19-38.
65. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J (2001). Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens, 10: 321-29.
66. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J (2003). Inflammation and angiotensin II. Int J Biochem Cell Biol, 35: 881-900.
67. Zalba G, San Jose G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, Diez J (2001). Oxidative stress in arterial hypertension. Role of NADPH oxidase. Hypertension, 38: 1395-1399.
68. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T (1999). Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens, 17: 537-545.
69. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T (1999). Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension, 33: 335-339.
70. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res, 87(5): E1-9.
71. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H (2007). The emerging role of ACE2 in physiology and disease. J Pathol, 212(1): 1-11.
72. Bacani C, Frishman WH (2006). Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev, 14(4):187-93.
73. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY (2001). Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem, 276(52):48623-6.
74. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA, 100(14): 8258-63.
75. Clark MA, Diz DI, Tallant EA (2001). Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension, 37(4):1141-6.
76. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T (2005). G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation, 111(14): 1806-13.
77. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD (2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109: 1417-27.
78. Nguyen G (2011). Renin, (pro)renin and receptor: an update. Clin Sci (Lond), 120(5): 169-78.
79. Nguyen G (2006). Renin/prorenin receptors. Kidney Int, 69(9):1503-6.
80. Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M (2007). Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol, 292(1): R274-82.
81. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T (2006). Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol, 17: 1950-61.
82. Nguyen G, Contrepas A (2008). The (pro)renin receptors. J Mol Med, 86: 643-46.
83. Nguyen G, Burcklé CA, Sraer JD (2004). Renin/prorenin-receptor biochemistry and functional significance. Curr Hypertens Rep, 6: 129-132.
84. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, PandolfiPP, Ruiz P, Unger T, Funke-Kaiser H (2006). A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res, 99: 1355-66.
85. Shan Z, Cuadra AE, Sumners C, Raizada MK (2008). Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol, 93: 701-18.
86. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T (2004). Inhibition of diabetic nephropathy by a decoy peptide corresponding to the handle region for nonproteolytic activation of prorenin. J Clin Invest, 114: 1128-35.
87. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H (2007). Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol, 18: 1789-95.
88. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R (2004). Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept, 120: 5-13.
89. Re RN (2003). Intracellular renin and the nature of intracrine enzymes. Hypertension, 42: 117-22.
90. Kumar R, Singh VP, Baker KM (2007). The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab, 18(5): 208-14.
91. Kumar R, Singh VP, Baker KM (2009). The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep, 11(2): 104-10.
92. Benigni A, Cassis P, Remuzzi G (2010). Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med, 2(7): 247-57.
93. Marchesi C, Paradis P, Schiffrin EL (2008). Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci, 29(7):367-74.
94. Heymes C, Silvestre JS, Llorens-Cortes C, Chevalier B, Marotte F, Levy BI, Swynghedauw B, Samuel JL (1998). Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology, 139: 2579-87.
95. Touyz RM, Endemann D, He G, Li JS, Schiffrin EL (1999). Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension, 33: 366-72.
96. Mukai Y, Shimokawa H, Higashi M, Morikawa K, Matoba T, Hiroki J, Kunihiro I, Talukder HM, Takeshita A (2002). Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol, 22: 1445-50.
97. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserta F (2005). Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept, 128: 247-52.
98. de Cavanagh EM, Piotrkowski B, Fraga CG (2004). Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med, 25(1-2): 27-36.
99. de Cavanagh EM, Inserra F, Ferder L (2011). Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res, 89(1): 31-40.
100. Thompson MM, Oyama TT, Kelly FJ, Kennefick TM, Anderson S (2000). Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol, 279(5): R1787-94.
101. Cassis P, Conti S, Remuzzi G, Benigni A (2010). Angiotensin receptors as determinants of life span. Pflugers Arch, 459(2): 325-32.
102. Min LJ, Mogi M, Iwai M, Horiuchi M (2009). Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res Rev, 8(2): 113-21.
103. de Cavanagh EM, Inserra F, Ferder M, Ferder L (2007). From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol, 27: 545-553.
104. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G (2009). Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest, 119: 524-30.
105. Umemoto S (2008). Angiotensin II type 1 (AT1) receptor deficiency halts the progression of age-related atherosclerosis in hypercholesterolemia: molecular link between the AT1 receptor and hypercholesterolemia. Hypertens Res, 31: 1495-7.
106. Harding JW, Sullivan MJ, Hanesworth JM, Cushing LL, Wright JW (1988). Inability of [125I]Sar1, Ile8-angiotensin II to move between the blood and cerebrospinal fluid compartments. J Neurochem, 50(2): 554-7.
107. Saavedra JM (2005). Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol, 25: 485-512.
108. von Bohlen und Halbach O, Albrecht D(2006). The CNS renin-angiotensin system. Cell Tissue Res, 326(2): 599-616.
109. Phillips MI, de Oliveira EM (2008). Brain renin angiotensin in disease. J Mol Med, 86: 715-22.
110. Cuadra AE, Shan Z, Sumners C, Raizada MK (2010). A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol Ther, 125: 27-38.
111. Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR (1988). Astrocytes synthesize angiotensinogen in brain. Science, 242: 1444-1446.
112. Milsted A, Barna BP, RansohoffRM, Brosnihan KB, Ferrario CM (1990). Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. Proc Natl Acad Sci USA, 87: 5720-5723.
113. Kumar A, Rassoli A, Raizada MK (1988). Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J Neurosci Res, 19: 287-290.
114. Thomas WG, Greenland KJ, Shinkel TA, Sernia C (1992). Angiotensinogen is secreted by pure rat neuronal cell cultures. Brain Res, 588: 191-200.
115. Hermann K, McDonald W, Unger T, Lang RE, Ganten D (1984). Angiotensin biosynthesis and concentrations in brain of normotensive and hypertensive rats. J Physiol (Paris), 79(6): 471-80.
116. Wang G, Anrather J, Huang J, Speth RC, Pickel V, Iadecola C (2004). NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius. J. Neurosci, 24: 5516-5524.
117. Ganten D, Minnich JL, Granger P, Hayduk K, Brecht HM, Barbeau A, Boucher R, Genest J (1971). Angiotensin-forming enzyme in brain tissue. Science, 173(991): 64-5.
118. Fuxe K, Ganten D, Hökfelt T, Locatelli V, Poulsen K, Stock G, Rix E, Taugner R (1980). Renin-like immunocytochemical activity in the rat and mouse brain. Neurosci Lett, 18: 245-250.
119. Dzau VJ, Brenner A, Emmett NL (1982). Evidence for renin in rat brain: differentiation from other renin like enzymes. Am J Physiol, 242: E292-E297.
120. Slater EE, Defendini R, Zimmerman EA (1980). Wide distribution of immunoreactive renin in nerve cells of human brain. Proc Natl Acad Sci USA, 77: 5458-5460.
121. Dzau VJ,. Ingelfinger J, Pratt RE, Ellison KE (1986). Identificacion of renin and angiotensinogen messenger RNA sequences in mouse and rat brains. Hypertension, 8: 544-548.
122. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature, 445: 168-176.
123. Morimoto S, Cassell MD, Sigmund CD (2002). The brain renin-angiotensin system in transgenic mice carrying a highly regulated human renin transgene. Cir Res, 90: 80-86.
124. Bader M and Ganten D (2002). It's renin in the brain. Transgenic animals elucidate the brain renin-angiotensin system. Circ Res, 90: 8-10.
125. Lavoie JL, Cassell MD, Gross KW, Sigmund CD (2004). Localization of renin expressing cells in the brain, by use of a REN-eGFP transgenic model. Physiol Genomics, 16: 240-246.
126. Allen AM, O'Callaghan EL, Hazelwood L, Germain S, Castrop H, Schnermann J, Bassi JK (2008). Distribution of cells expressing human renin-promoter activity in the brain of a transgenic mouse. Brain Res, 1243: 78-85.
127. Valenzuela R, Barroso-Chinea P, Muñoz A, Joglar B, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL (2010). Location of prorenin receptors in primate substantia nigra. Effects on dopaminergic cell death. J Neuropathol Exp Neurol, 69(11):1130-42.
128. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M (1985). Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med, 312: 1412-1217.
129. Peng J, Kimura B, Phillips MI (2002). The predominant role of brain angiotensinogen and angiotensin in environmentally induced hypertension. Regul Pept, 110(1): 25-32.
130. Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ (2007). Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry, 31(5): 1113-8.
131. Maul B, Krause W, Panlow K, Becker M, Gembardt F, Alenina N, Walther T, Bader M, Siems WE (2005). Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J, 19(11): 1474-81.
132. Kerr DS, Bevilaqua LR, Bonini JS, Rossato JI, Köhler CA, Medina JH, Izquierdo I, Cammarota M (2005). Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl), 179(3): 529-35.
133. Hellner K, Walther T, Schubert M, Albrecht D (2005). Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci, 29(3):427-35.
134. Stier CT Jr, Adler LA, Levine S, Chander PN (1993). Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl, 11(3): S37-42.
135. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U, Unger T (2005). Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J, 19: 617-619.
136. Lou M, Blume A, Zhao Y, Gohlke P, Deuschl G, Herdegen T, Culman J (2004). Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab, 24: 536-547.
137. Savaskan E (2005). The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res, 2(1): 29-35.
138. Kehoe PG, Wilcock GK (2007). Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol, 6(4): 373-8.
139. Mogi M, Horiuchi M (2009). Effects of angiotensin II receptor blockers on dementia. Hypertens Res, 32(9):738-40.
140. Quinlan JT, Phillips MI (1981). Immunoreactivity for angiotensin II-like peptide in the human brain. Brain Res, 205: 212-218.
141. Brownfield MS, Reid IA, Ganten D, Ganong WF (1982). Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain. Neuroscience 7: 1759-1769.
142. Chai SY, Mendelsohn FAO, Paxinos G (1987). Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience 20: 615-627.
143. Allen AM, MacGregor DP, Chai SY, Donnan GA, Kaczymarzyk S, Richardson K, Kalnins R, Ireton J, Mendelsohn FAO (1992). Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol, 32: 339-344.
144. 2) receptor mRNAs in the adult rat brain: A functional neuroanatomical review. Front Neuroendocrinol, 18: 383-39.
145. Simonnet G, Giorguieff-Chesselet MF, Carayon A, Bioulac B, Cesselin F, Glowinski J, Vincent JD (1981). Angiotensin II and the nigrostriatal system. J Physiol, 77: 71-79.
146. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL (2008). Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis, 31: 58-73.
147. Joglar B, Rodriguez-Pallares J, Rodríguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL (2009). The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem, 109: 656-669.
148. Eggena P, Zhu JH, Sereevinyayut S, Giordani M, Clegg K, Andersen PC, Hyun P, Barrett JD (1996). Hepatic angiotensin II nuclear receptors and transcription of growth-related factors. J Hypertens, 14: 961-68.
149. Lu D, Yang H, Shaw G, Raizada MK (1998). Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology, 139: 365-75.
150. Chen R, Mukhin YV, Garnovskaya MN, Thielen TE, Iijima Y, Huang C, Raymond JR, Ullian ME, Paul RV (2000). A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation. Am J Physiol Renal Physiol, 279: F440-448.
151. Khan F, Spicarová Z, Zelenin S, Holtbäck U, Scott L, Aperia A (2008). Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol, 295: F1110-1116.
152. Gildea JJ (2009). Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens, 18: 28-32.
153. Zeng C, Liu Y, Wang Z, He D, Huang L, Yu P, Zheng S, Jones JE, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA (2006). Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res, 99: 494-500.
154. Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA (2008). Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest, 118: 2180-2189.
155. Villar-Cheda B, Rodríguez-Pallares J, Muñoz A, Valenzuela R, Guerra MJ, Baltatu OC, Labandeira-Garcia JL (2010). Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur J Neurosci, 32: 1695-1706.
156. Gelband CH, Zhu M, Lu D, Reagan LP, Fluharty SJ, Posner P, Raizada MK, Sumners C (1997). Functional interactions between neuronal AT1 and AT2 receptors. Endocrinology, 138: 2195-2198.
157. Ferrari R, Guardigli G, Cicchitelli G, Valgimigli M, Merli E, Soukhomorskaia O, Ceconi C (2002). Angiotensin II overproduction: enemy of the vessel wall. Eur Heart J, 4 Suppl A: A26-A30.
158. Mendelsohn FAO, Jenkins TA, Berkovic SF (1993). Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat. Brain Res, 613: 221-229.
159. Brown DC, Steward LJ, Ge J, Barnes NM (1996). Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. British J Pharmacol, 18: 414-420.
160. Hussain T, Abdul-Wahab R, Kotak DK, Lokhandwala MF (1998). Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension, 32: 1054-1059.
161. Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA (2007). The dopaminergic system in hypertension. Clin Sci (Lond), 112: 583-597.
162. Jenkins TA, Mendelsohn FAO, Chai SY (1997). Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem, 68: 1304-1311.
163. Jenkins TA, Wong JYF, Howells DW, Mendelsohn FAO (1999). Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in MPTP-treated mouse. J Neurochem, 73: 214-219.
164. Reardon KA, Mendelsohn FA, Chai SY, Horne MK (2000). The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinsońs disease. Aust N Z Med, 30: 48-53.
165. Konings CH, Kuiper MA, Bergmans PL, Grijpma AM, van Kamp GJ, Wolters EC (1994). Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinsońs disease. Clin Chim Acta, 23: 101-106.
166. Lin JJ, Yueh KC, Chang DC, Lin SZ (2002). Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson disease. J Neurol Sci, 199: 25-29.
167. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL (2005). Angiotensin-converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J Neurosci Res, 81: 865-873.
168. Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL (2006). Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology, 51: 112-120.
169. Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL (2007). Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging, 28: 555-567.
170. Wang G, Anrather J, Glass MJ, Tarsitano MJ, Zhou P, Frys KA, Pickel VM, Iadecola C (2006). Nox2, Ca2+, and protein kinase C play a role in angiotensin II-induced free radical production in nucleus tractus solitarius. Hypertension, 48: 482-489.
171. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL, (2010). Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging. PMID: 20888078.
172. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH (2003). Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res, 964: 288-94.
173. Sohn HY, RaffU, Hoffmann A, Gloe T, Heermeier K, Galle J, Pohl U (2000). Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol, 131: 667-672.
174. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM (2002). Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem, 80: 168-77.
175. Callier S, Le Saux M, Lhiaubet AM, Di Paolo T, Rostène W, Pelaprat D (2002). Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture. J Neurochem, 80: 307-316.
176. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr (2000). Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci, 20: 8604-8609.
177. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF (2004). Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol, 61: 886-888.
178. Ragonese P, D'Amelio M, Callari G, Salemi G, Morgante L, Savettieri G (2006). Age at menopause predicts age at onset of Parkinson's disease. Mov Disord, 21: 2211-2214.
179. Ragonese P, D'Amelio M, Savettieri G (2006). Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann N Y Acad Sci, 1089: 373-382.
180. Popat RA, Van Den Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM (2005). Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology, 65: 383-390.
181. Shulman LM (2002). Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord, 8: 289-95.
182. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E, Marchetti B (2006). Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience, 138: 869-878.
183. Tripanichkul W, Sripanichkulchai K, Finkelstein DI (2006). Estrogen down- regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res, 1084: 28-37.
184. Chen J, Yang S, Hu S, Choudhry MA, Bland KI, Chaudry IH (2008). Estrogen prevents intestinal inflammation after trauma-hemorrhage via downregulation of angiotensin II and angiotensin II subtype I receptor. Am J Physiol Gastrointest Liver Physiol, 295: G1131-7.
185. Dean SA, Tan J, O'Brien ER, Leenen FH (2004). 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol, 288: R759-766.
186. Nickenig G, Bäumer AT, Grohè C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Böhm M (1998). Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation, 97: 2197-201.
187. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, Cui TX, Horiuchi M (2002). Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension, 40: 451-457.
188. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M (2005). Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension, 45: 545-551.
189. Xue B, Pamidimukkala J, Lubahn DB, Hay M (2007). Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol, 292: H1770-1776.
190. Hoshi-Fukushima R, Nakamoto H, Imai H, Kanno Y, Ishida Y, Yamanouchi Y, Suzuki H (2008). Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am J Nephrol, 28: 413-423.
191. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL (2010). Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp Neurol, 224: 517-26.
192. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288: 321-33.
193. Clarkson TB, Mehaffey MH (2009). Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol, 71: 785-93.
194. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, WHI Investigators (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304: 1684-92.
195. Turgeon JL, McDonnell DP, Martin KA, Wise PM (2004). Hormone therapy: physiological complexity belies therapeutic simplicity. Science, 304: 1269-73.
196. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM (2006). Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev, 27: 575-605.
197. Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Naftolin F, Santoro N (2005). Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol, 99: 381-3.
198. Miller VM, Black DM, Brinton EA, BudoffMJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM (2009). Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res, 2: 228-39.
199. Harman SM, Naftolin F, Brinton EA, Judelson DR (2005). Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci, 1052: 43-56.